Clinical examples
In clinical trials, XHANCE significantly improved nasal congestion at Week 4 and significantly reduced bilateral polyp grade at Week 16 (coprimary endpoints)1:
- Average reduction in congestion using a 0-3 point scale: 0.62 XHANCE 372 mcg BID vs 0.24 EDS-placebo (P<0.001)
- Average reduction of polyp grade in a clinical trial using a 0-3 point scale: 1.41 XHANCE 372 mcg BID vs 0.61 EDS-placebo (P<0.001)
Endoscopic video examples of the impact of XHANCE
Patient 1
Reduction from grade 2 to grade 1
Patient 2
Reduction from grade 2 to grade 0
Patient 3
Improvement in SNOT-22 score
These results may not be representative of all patients using XHANCE.
A side-by-side example2
- Patient experienced polyp recurrence following endoscopic sinus surgery
- Grade 2 nasal polyp located in the left nasal cavity confirmed by rigid endoscopy
- Patient was not taking any medication for the treatment of nasal polyps but was being treated for asthma
![Before Xhance & after using Xhance for 3 months photos](/wp-content/themes/xhance-2018/dist/images/5_2_Endoscopy_Image.png)
The clinical trials for XHANCE evaluated over 1500 patients.2
See what makes XHANCE different.